![]() In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive BLU- 222 to treat patients with cyclin E aberrant cancers and BLU-852 for the treatment of advanced cancers. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC) and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders and Fisogatinib. Review their curricula to ensure they create cohorts of doctors with a broad base of skills, able to develop into specialists as their careers progress.Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. widen the pool of clinical educators to facilitate expansion.address the challenges and opportunities facing the clinical academic workforce in the people plan, including year-on-year growth and the development of clear clinical academic career pathways to create a sustainable pipeline to meet future demand.consult with medical schools about moving towards an apprenticeship-style final year of medical school when developing expansion plans.ensure that expansion proposals are informed by the Selection Alliance reports, which provide a wealth of insight into the areas that need a greater focus.consider an increase in undergraduate foundation years for medicine as part of a strategic approach to NHS workforce planning.undertake further detailed work to fully understand the potential undergraduate applicant pool, asking UCAS to carry out research with potential applicants to medical school and other science subjects to understand the appetite for places and the perceptions of the entry process to medicine.build on the successful work of the previous expansion to provide medical school education across the whole of England.ensure that an expansion of places and the process of allocating places incentivises an increased focus on widening participation in medicine.double the number of medical school places from 7,500 to 15,000 per year, at an annual cost of around £1.85bn.We should take the opportunity to do just that. But we do believe there is a need across the country to realign the graduate attributes of medical school students with the needs and realities of the health and care system. ![]() There is no one-size-fits-all approach and we are not suggesting that there should be. While its focus is on undergraduate medical education in England, at times it draws on data and considers what is happening in Wales, Scotland and Northern Ireland. We hope this report will provoke discussion and debate about the future of medical student training in the UK. ![]() ![]() We need to consider and respond to the immediate challenges, but also look over the horizon. It is vital that we now take stock and plan for the next 10 years. Even with decisive action, it is going to take at least a decade to get the NHS workforce back on a sustainable footing. The challenges facing the NHS workforce are significant. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |